Product Description
Mechanisms of Action: CYP3A4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alaunos Therapeutics
Company Location: BOSTON MA 02129
Company CEO: Kevin S. Boyle
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Scleroderma, Diffuse|Breast Cancer|Scleroderma, Systemic|Scleroderma, General|Scleroderma, Localized|Brain Cancer|Glioma|Glioblastoma
Phase 1: Glioblastoma|Glioma|Astrocytoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATI001-103 | P2 |
Terminated |
Brain Cancer|Glioma |
2021-09-10 |
55% |
| ATI001-103 | P2 |
Terminated |
Brain Cancer|Glioma |
2021-09-10 |
55% |
| ATI001-204 | P2 |
Terminated |
Glioblastoma |
2021-08-05 |
|
| Protocol ATI001-102 Substudy | P1 |
Completed |
Glioblastoma |
2020-10-15 |
42% |
| Protocol ATI001-102 Substudy | P1 |
Completed |
Glioblastoma |
2020-10-15 |
42% |
| Morphea | P2 |
Terminated |
Scleroderma, General|Scleroderma, Systemic|Scleroderma, Localized|Scleroderma, Diffuse |
2020-09-23 |